Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, adjuvant

Indication(s)

• Breast Cancer; ICD-10 C50.-

Cycles

Cycle length 21 days, recommended cycles: 4

Protocol sequences

• EC (EPIR90/CYCL600), Breast Ca, adj. (PID579) -|- PACL80, Breast Ca, adj. (PID581)
• Neoadjuvant WSG-TP-II (Paclitaxel)
• Neoadjuvant WSG-TP-II (Letrozole)
• Neoadjuvant WSG-TP-II (Tamoxifen) -|- PERT840/TRAS8/TMXF20, Breast Ca, adj., C1 (PID2450)

References

• Sparano JA, Weekly paclitaxel in the adjuvant treatment of breast cancer., N Engl J Med 2008 Apr 17;358(16):1663-71 [PMID]
• von Minckwitz G, Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study., J Clin Oncol 2010 Apr 20;28(12):2015-23 [PMID]
• De Laurentiis M, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials., J Clin Oncol 2008 Jan 1;26(1):44-53 [PMID]
• Smith LA, Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials., BMC Cancer 2010;10:337 [PMID]
• Khasraw M, Epirubicin: is it like doxorubicin in breast cancer? A clinical review., Breast 2012 Apr;21(2):142-9 [PMID]

Recommendations

• 08/2019: European Society for Medical Oncology
• 03/2023: National Comprehensive Cancer Network

Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.

The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 18.09.2023